Neurogene Q2 FY26 net loss widens to USD 34.49 million

NGNE•2026-08-11

Q2 net loss widens

Neurogene posted a Q2 net loss of USD 34.49 million, widening from USD 22.02 million a year earlier.

Cash position and program update

Cash, cash equivalents and short-term investments totaled USD 225.4 million at June 30; pro forma liquidity was about USD 360.2 million post-offering.

NGN-401 Phase 1/2 data showed 100% of participants improved on CGI-I; Embolden topline data are expected in 2H 2027.

Costs rise on clinical and pre-commercial spending

R&D costs rose to USD 25.47 million from USD 19.37 million, driven by higher NGN-401 clinical and CMC spending.
G&A expense climbed to USD 11.2 million from USD 6.72 million on higher stock-based compensation and pre-commercial activity.

Neurogene Q2 FY26 net loss widens to USD 34.49 million

Q2 net loss widens

Cash position and program update

Costs rise on clinical and pre-commercial spending

Related News

Axil Brands updates financial calendar with fiscal Q4, full-year earnings release and investor call

Protara Therapeutics Q2 net loss widens on higher expenses

Dominari Holdings Q2 revenue falls on fewer deal closings

Tanger begins renovation of 500,000-sq-ft Tanger Outlets Foley, adds 20,000-sq-ft dining zone

Viavi EVP and Chief Marketing & Strategy Officer Paul McNab sells 1,595 shares worth $59,593.15